Amgen Inc.
AMGN Healthcare Drug Manufacturers General
Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024. In the quarter to June 2026, revenue grew 9.53%, EPS grew 65.4%, free cash flow grew 82.6% and total debt rose 1.96%, each against the same quarter a year earlier. Member of the S&P 500, Nasdaq 100 and Dow Jones; dividend growth for ten consecutive years, revenue growth for five.
Follow AMGN
Amgen Inc. (AMGN) EV/FCF
As of 9 October 2026, Amgen Inc. (AMGN) trades at a EV/FCF of 27.4×. Over the past ten years it has ranged from 10.7× (September 2015) to 46.5× (September 2024); the current reading is higher than 87% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 28.9× | 53.05% |
| FY2024 | 18.9× | (38.54%) |
| FY2023 | 30.7× | 50.57% |
| FY2022 | 20.4× | 5.64% |
| FY2021 | 19.3× | 16.27% |
| FY2020 | 16.6× | (19.37%) |
| FY2019 | 20.6× | 56.47% |
| FY2018 | 13.2× | 7.85% |
| FY2017 | 12.2× | 2.60% |
| FY2016 | 11.9× | (12.27%) |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Jun 2026 | 24.5× | (14.93%) |
| Mar 2026 | 28.8× | (0.28%) |
| Dec 2025 | 28.9× | 62.95% |
| Sep 2025 | 17.7× | (9.07%) |
| 42 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| BMY Bristol Myers Squibb Company compare | 13.4× |
| GILD Gilead Sciences, Inc. compare | 16.3× |
| NVS Novartis AG compare | 20.6× |
| PFE Pfizer Inc. compare | 20.9× |
| NVO Novo Nordisk A/S compare | 24.4× |
| MRK Merck & Co., Inc. compare | 25.1× |
| AMGN Amgen Inc. | 27.4× |
| ABBV AbbVie Inc. compare | 30.4× |
| AZN AstraZeneca PLC compare | 43.3× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on AMGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement